Navigation Links
$1.9 million NIH grant supports research in the most common soft tissue tumor in children
Date:2/20/2011

A nearly $2 million grant from the National Institutes of Health (NIH) will help investigators at Nationwide Children's Hospital search for biomarkers that may be linked to the development and outcome of hemangiomas, the most common soft tissue tumor in children. Nationwide Children's is home to the only Hemangioma and Vascular Malformations Clinic in the United States with an NIH-sponsored clinical study.

A hemangioma is an abnormal buildup of blood vessels in the skin or internal organs. Hemangiomas appear as a red to reddish-purple, raised lesion or as a massive, raised tumor.

"Hemangiomas can be extremely disfiguring and life-threatening, resulting in significant distress for the families of affected children," said the grant's principal investigator, Gayle Gordillo, MD, director of the Hemangioma and Vascular Malformations Clinic in Plastic and Reconstructive Surgery at Nationwide Children's Hospital. "A critical barrier to improving the clinical outcomes for affected children is the lack of low-risk treatment options. The most effective treatment options all have life-threatening side effects."

Dr. Gordillo's laboratory research using a mouse-model has shown that the formation of these soft tissue tumors depends on nox-4. Nox-4 is an enzyme involved in the production of reactive oxygen species, a natural part of a healthy cellular environment. However, excessive production of reactive oxygen species can result in significant damage to the cell.

As part of the NIH-funded study, Dr. Gordillo and colleagues at both Nationwide Children's Hospital and The Ohio State University Medical Center, will examine urine and blood samples from patients with hemangioma beginning from the time they enroll in the study until they are 2 years of age. They will also perform ultrasound on each patient to measure the size of the hemangioma and velocity of the blood flowing to the tumor. Recruitment for study participants will take place at Nationwide Children's.

By comparing samples from these patients with samples from age-matched healthy children, Dr. Gordillo's team will be able to investigate how nox-4 regulates growth of endothelial cells that develop into tumors. They will also search to determine whether biological products caused by nox-4 function can be used as biomarkers to determine patient outcome.

"This is the first prospective, longitudinal study aimed at identifying biomarkers in children with hemangiomas," said Dr. Gordillo, also a faculty member at The Ohio State University College of Medicine. "Our goal is to further understand the role oxidant production has on hemangioma formation. Our findings could help identify potential new treatment targets and establish biomarkers that can be used to design clinical trials to test new therapeutics to treat these soft tissue tumors."


'/>"/>

Contact: Mary Ellen Peacock
MaryEllen.Peacock@NationwideChildrens.org
614-355-0495
Nationwide Children's Hospital
Source:Eurekalert

Related medicine news :

1. 3.1 Million Hispanic Americans Struggle With Arthritis
2. 4.7 million Californians to gain coverage under health reform, new study estimates
3. Fossil Suggests Humans Walked Upright 3 Million Years Ago
4. Johns Hopkins School of Medicine grants $5 million to study cognitive disorders
5. Apica Cardiovascular receives $5.1 million investment for improved heart surgery system
6. Researchers predict nearly 1.3 million cancer deaths in Europe in 2011
7. MDA awards $13.5 million in grants for research treatments for neuromuscular diseases
8. U-M Medical School researchers set new record in NIH funding: $368.7 million
9. UofL awarded $9.56 million to form first-ever multicenter cardiovascular research network
10. $2.8 million grant boosts cystic fibrosis research at Queens
11. Cedars-Sinai research team awarded $1.9 million from CIRM to develop new tools and technologies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... ... March 24, 2017 , ... Clean Earth, ... material, and hazardous and non-hazardous materials announced today the acquisition of privately owned ... will add four additional processing facilities and a vast array of additional technologies, ...
(Date:3/24/2017)... ... , ... The Radiology Business Management Association (RBMA) has named the ... their 12th year, are among the most prestigious in radiology marketing because a panel ... retooled to recognize achievements in both large budget (over $5,000) and small budget (under ...
(Date:3/24/2017)... (PRWEB) , ... March 24, 2017 , ... ... Center, Sedona, Arizona’s Premier Center for Shamanic Healing and Spiritual Awakening, proudly ... Delgado, June 9--24, 2017. This sacred and spiritual journey during the Summer ...
(Date:3/24/2017)... ... March 24, 2017 , ... The law firm of Enea, Scanlan & ... announce Westchester resident Lauren C. Enea has joined the firm as an associate attorney. ... her practice in elder law, Medicaid planning and applications, and Wills, Trusts and Estates. ...
(Date:3/24/2017)... ... March 24, 2017 , ... “Finding Christ Through ... a devotional journal chronicling the writer’s path toward true communion with God. “Finding ... God #TruthwithGrace” is the creation of published author Lea Michelle Johnson, a follower ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)...  HealthMine surveys with 9,250 insured consumers fielded from ... members want help from their plans in five key ... health, 2) help closing gaps in care, 3) better ... 5) relevant, real-time guidance. Meeting these needs is essential ... A Reason to Stay Engaged in ...
(Date:3/24/2017)... , March 23, 2017  Provectus Biopharmaceuticals, Inc. ... "Company"), a clinical-stage oncology and dermatology biopharmaceutical company, ... Financing Commitment Term Sheet (the "Definitive Financing") it ... of the Company,s stockholders, who are referred to ... a Form 8-K filed with the Securities and ...
(Date:3/24/2017)... Mar 24, 2017 The Board of Directors ... Annual Report 2016 including the complete 2016 Annual Accounts with ... on Nordic Nanovector,s website in the section Investor Relations/Reports and ... ... Tone Kvåle, Chief Financial Officer Cell: +47-91-51-95-76 Email: ir@nordicnanovector.com ...
Breaking Medicine Technology: